Aim: Stereotactic body radiation therapy (SBRT) is a technique that utilises precisely targeted radiation to a tumour while minimising radiation to adjacent normal tissue. The targeting allows treatment of small or moderate-sized tumours in either 3, 5 or 8 fractions. SBRT is increasingly being used to treat patients with medically inoperable stage I non-small cell lung cancer and has been reported to be safe and effective. The aim of this study is to review our centre's results with SBRT. Methods: We carried out a retrospective review of 136 patients with early-stage lung cancer who received SBRT. Prior to treatment patients were evaluated with regards to tumour stage and histology, co-morbidities, WHO performance status and lung function test. Following treatment, patients were assessed at 2 and 6 weeks, then at 3 monthly interval in the first year, 6 monthly interval in the second year then yearly up to 5 years. Outcome measures included CTCTAE v4.0 toxicity profile and response to treatment.
